Claims for Patent: 9,321,999

Summary for Patent: 9,321,999

Title:	Compositions for increasing polypeptide stability and activity, and related methods
Abstract:	This disclosure provides peptides, polypeptides, fusion polypeptides, compositions, and methods for enhancing or increasing the stability of a polypeptide (e.g., Taq polymerase). Such peptides, polypeptides, fusion polypeptides, or compositions include polypeptides linked to a peptide tag that enhances the stability of the polypeptide. The peptides, polypeptides, fusion polypeptides, compositions may also enhance the activity, specificity, and/or fidelity of other polypeptides in a reaction mixture. The disclosure also provides methods of using such peptides, polypeptides, fusion polypeptides, compositions.
Inventor(s):	Kahre; Olev (Tartu, EP), Artma; Kadri (Tartumaa, EP), Kahre; Tiina (Tartu, EP)
Assignee:	SOLIS BIODYNE OU (Tartu, EE)
Application Number:	12/950,349
Patent Claims:	1. A method of increasing the thermal stability of a polypeptide comprising covalently linking the polypeptide at the amino-terminus to a peptide tag to form a fusion polypeptide, wherein: (a) the peptide tag is at least 95% identical to SEQ ID NO: 1; and (b) the fusion polypeptide does not have the amino acid sequence of SEQ ID NO: 2. 2. The method of claim 1, wherein the peptide tag has an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 16. 3. The method of claim 1, wherein the peptide tag is encoded by a nucleic acid sequence of SEQ ID NO: 3 or SEQ ID NO: 17. 4. The method of claim 1, wherein the peptide tag comprises at least three histidine residues. 5. The method of claim 1, wherein the polypeptide is erythropoietin, human Leukemia Inhibitory Factor (hLIF), granulocyte macrophage colony-stimulating factor (GM-CSF), insulin, vascular endothelial growth factor (VEGF), leptin, or bevacizumab. 6. The method of claim 1, wherein the fusion polypeptide comprises the amino acid sequence of SEQ ID NO: 20 or SEQ ID NO: 22. 7. The method of claim 1, wherein the polypeptide is a thermostable protein or enzyme. 8. The method of claim 7, wherein the enzyme is a polymerase, reverse transcriptase, nuclease, pyrophosphatase, deaminase, or protease. 9. The method of claim 8, wherein the polymerase is a DNA polymerase I, Thermus aquaticus DNA polymerase I (Taq), Thermococcus gorgonarius DNA polymerase (Tgo), Thermus thermophilics (Tth) DNA polymerase, or ZO5 DNA polymerase. 10. The method of claim 8, wherein the pyrophosphatase is a Thermoplasma acidophilum pyrophosphatase (TAPP). 11. The method of claim 8, wherein the deaminase is a Pyrococcus horikoshii dCTP deaminase. 12. The method of claim 7, wherein the thermostable protein is a cosmetic peptide or polypeptide. 13. The method of claim 1, wherein the polypeptide comprises at least two polypeptides. 14. The method of claim 13, wherein the polypeptide comprises an enzyme and a double strand binding protein. 15. The method of claim 14, wherein the double strand binding protein comprises an amino acid sequence of SEQ ID NO: 10. 16. The method of claim 1, wherein the peptide tag is at least 98% identical to SEQ ID NO:1. 17. The method of claim 1, wherein covalently linking the polypeptide causes the polypeptide to have thermal stability at 35.degree. C. 18. The method of claim 1, wherein covalently linking the polypeptide causes the polypeptide to have thermal stability at -20.degree. C.

Details for Patent 9,321,999

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2029-11-19